Clinical Trial Update: The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing whether terlipressin can prevent Type 2 hepatorenal syndrome by improving mean arterial pressure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatorenal Syndrome

Drugs mentioned

• Terlipressin (terlipressin)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatorenal Syndrome | Phase 4 | Status: UNKNOWN